Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Patients were randomized into three different treatment arms for 48 hours: Bolus group (bl) = furosemide 80 mg IV boluses, twice daily Continuous group (cIv) = IV furosemide 160 mg/day, given as a continuous infusion over 16 hours Hyperdiuresis group (HSS) = 160 mg IV furosemide plus 150 ml of 2% NaCl, twice daily infused over 30 minutes Patients in the hyperdiuresis group had shorter hospital length of stay (table below)
Review your marketing
The goal is finding the concentration sweet spot where doses fall in a range that is both easy to measure accurately and comfortable to inject
Unlike traditional anti-inflammatory drugs that simply suppress inflammation, BPC-157 helps resolve it appropriately, so the healing process can proceed without the tissue damage caused by chronic inflammation
Professor Goldsteins research contributions include: Co-discovery and isolation of the thymosin family of peptides in the 1960s First clinical trials of thymosin preparations in immunodeficient children (1974) Characterization of thymosin beta-4s actin-binding and wound healing properties Development of therapeutic applications for tissue repair and regeneration Over 450 published scientific articles and 25+ patents related to thymosins Leadership in translating thymosin research toward clinical development Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to BPC-157 and TB-500/thymosin beta-4 research
US$ 23.52
US$ 21.68
US$ 21.60
US$ 24.81
US$ 21.76
US$ 21.99
